View Original / Current protocol   |  | 
Registration number   |  | 
Date of registration in ChiCTR   |  | 
 | Retrospective registration   | 
 | 吉西他滨、左旋门冬酰胺酶、异环磷酰胺、地塞米松及足叶乙甙(GLIDE)方案治疗初发III/IV期及复发难治侵袭性NK/T细胞淋巴瘤的临床试验   | 
 | 吉西他滨、左旋门冬酰胺酶、异环磷酰胺、地塞米松及足叶乙甙(GLIDE)方案治疗初发III/IV期及复发难治侵袭性NK/T细胞淋巴瘤的临床试验   | 
 |  | 
Ethics approval status   |  | 
Objectives of study   | 评价GLIDE方案治疗初治的III/IV期和复发难治的侵袭性NK/T细胞淋巴瘤的有效性和安全性   | 
Health condition(s) or problem(s) studied   | 侵袭性NK/T细胞淋巴瘤(结外鼻型NK/T细胞淋巴瘤,侵袭性NK/T细胞白血病)   | 
 |  | 
 |  | 
 |  | 
 |  | 
 |  | 
 | 1、经病理组织学及免疫组织化学确诊的I/II期鼻型NK/T淋巴瘤患者。2、ECOG评分0-2分,无化疗禁忌症。3、预计生存期3个月以上。4、患者自愿参加并签署知情同意书。   | 
 | 1、妊娠妇女或正在哺乳期妇女;2、任何无法控制的临床问题(如严重的精神、神经、心血管、呼吸、活动性感染等系统疾病);3、已知对任何研究用药过敏的患者;   | 
 | 治疗组: 吉西他滨 800mg/m^2 D1,8,左旋门冬酰胺酶 6000mg/m^2 D8,10,12,14,16,18,20,异环磷酰胺1g/m^2 D1-3,地塞米松40mg D1-4,D9-12(肠道淋巴瘤第一疗程给与强的松100mg D1-5),足叶乙甙 100mg/m^2 D1-3。总疗程6-8疗程。  | 
 |  | 
 | 总生存期, 客观有效率, III-IV级毒性反应, 完全缓解率,   | 
 |  | 
 |  | 
Collecting sample(s) from participants   |  | 
 |  | 
 |  | 
Anticipated date of the first enrolment   |  | 
Anticipated date of the last enrolment   |  | 
 |  | 
 |  | 
Countries of recruitment [Province(s) and city(s)]   |  | 
Institution(s) or hospital(s)   |  | 
Organizer institution (leader institution)   |  | 
Institution responsible for collecting data   |  | 
 |  | 
Project number of funding source   |  | 
 |  | 
 |  | 
 |  | 
Date of application for trial registration   |  | 
Contact person for public queries   |  | 
Address of contact person   |  | 
Phone No. of contact person   |  | 
Postcode of contact person   |  | 
Fax No. of contact person   |  | 
Email of contact person   |  | 
 |  | 
Contact person for scientific queries   |  | 
Address of the trial leader   |  | 
Phone No. of the trial leader   |  | 
Postcode of the trial leader   |  | 
Fax No. of the trial leader   |  | 
Email of the trial leader   |  |